Furthermore, studies such as those from Marmouset et al. and Martin et al. highlighted how most of these patients developed t-MN characterized by an adverse risk cytogenetic and molecular profile, with over 60% of them bearing complex karyotypes and/or TP53 mutations [78,79]. This evidence concerns the gene TP53 and therapy-related myeloid neoplasm.